|
| InsiderPie Expert Score
| P/E ratio
| Net margin
| ROA
| Net income per employee
|
| Rigel Pharmaceuticals, Inc.
|
50
/ 100
| 3.6
| 36.5%
| 47.3%
| €515.04K
|
| Mersana Therapeutics, Inc.
|
50
/ 100
| -0.49
| -212.9%
| -87.5%
| -€619.12K
|
| Madrigal Pharmaceuticals, Inc.
|
43
/ 100
| -24
| -54.7%
| -27.8%
| -€455.39K
|
| ACADIA Pharmaceuticals Inc.
|
51
/ 100
| 17
| 21.8%
| 18.1%
| €290.19K
|
| Poseida Therapeutics, Inc.
|
50
/ 100
| -16
| -39.4%
| -20.2%
| -€144.76K
|
| Bellicum Pharmaceuticals, Inc.
|
50
/ 100
| -0.036
| -1,445.4%
| -318.1%
| -€1.43M
|
| MannKind Corporation
|
51
/ 100
| 35
| 10.9%
| 8.0%
| €69.42K
|
| Veru Inc.
|
51
/ 100
| -2.6
| -491.4%
| -119.7%
| -€132.86K
|
| BridgeBio Pharma, Inc.
|
49
/ 100
| -11
| -329.3%
| -71.9%
| -€913.44K
|
| Inovio Pharmaceuticals, Inc.
|
50
/ 100
| -0.57
| -16,239.9%
| -79.0%
| -€860.06K
|
| Medigene AG
|
50
/ 100
| -0.12
| -249.8%
| -57.8%
| -€191.39K
|
| Molecular Templates, Inc.
|
50
/ 100
| -0.000042
| -61.4%
| -58.5%
| -€214.97K
|
| Sino Biopharmaceutical Limited
|
50
/ 100
| 17
| 12.1%
| 5.4%
| €17.08K
|
| Futura Medical plc
|
50
/ 100
| -4.4
| -30.6%
| -38.4%
| -€427.59K
|
| Aadi Bioscience, Inc.
|
50
/ 100
| -9.1
| -48.2%
| -5.8%
| -€167.66K
|
| Autolus Therapeutics plc
|
50
/ 100
| -2.7
| -760.9%
| -31.6%
| -€300.28K
|
| Arrowhead Pharmaceuticals, Inc.
|
46
/ 100
| -15
| -18.4%
| -10.9%
| -€211.49K
|
| Protalix BioTherapeutics, Inc.
|
50
/ 100
| 20
| 10.1%
| 8.0%
| €25.13K
|
| Atara Biotherapeutics, Inc.
|
51
/ 100
| 9.3
| 3.1%
| 15.7%
| €32.31K
|
| Axsome Therapeutics, Inc.
|
45
/ 100
| -21
| -49.9%
| -38.6%
| -€295.78K
|
| MacroGenics, Inc.
|
50
/ 100
| -2.1
| -22.2%
| -14.8%
| -€91.05K
|
| Incyte Corporation
|
62
/ 100
| 15
| 19.0%
| 15.0%
| €283.84K
|
| ORIC Pharmaceuticals, Inc.
|
49
/ 100
| -6.4
| -25,750.3%
| -39.6%
| -€959.56K
|
| Regeneron Pharmaceuticals, Inc.
|
60
/ 100
| 12
| 31.4%
| 11.7%
| €250.89K
|
| Applied Genetic Technologies Corporation
|
50
/ 100
| 0
| -10,846.8%
| -61.5%
| -€294.79K
|
| Innoviva, Inc.
|
58
/ 100
| 32
| 10.4%
| 2.9%
| €259.57K
|
| Vericel Corporation
|
53
/ 100
| 296
| 2.9%
| 1.6%
| €16.98K
|
| OptiBiotix Health Plc
|
50
/ 100
| -3
| -253.9%
| -42.5%
| -€441.08K
|
| Sutro Biopharma, Inc.
|
49
/ 100
| -0.3
| -199.8%
| -79.5%
| -€661.74K
|
| Altimmune, Inc.
|
50
/ 100
| -3.2
| -438,730.0%
| -46.1%
| -€1.27M
|
| Jounce Therapeutics, Inc.
|
50
/ 100
| -1.9
| -62.1%
| -24.0%
| -€308.02K
|
| Capricor Therapeutics, Inc.
|
50
/ 100
| -7.3
| -522.5%
| -52.4%
| -€373.04K
|
| 4D pharma plc
|
50
/ 100
| 0
| -22,633.2%
| -56.1%
| -€258.48K
|
| Berkeley Lights, Inc.
|
50
/ 100
| -0.87
| -130.1%
| -33.3%
| -€299.38K
|
| Jaguar Health, Inc.
|
46
/ 100
| -0.081
| -345.4%
| -84.2%
| -€707.51K
|
| G1 Therapeutics, Inc.
|
50
/ 100
| -8.4
| -76.9%
| -45.4%
| -€381.87K
|
| Editas Medicine, Inc.
|
50
/ 100
| -0.81
| -608.9%
| -112.5%
| -€821.26K
|
| Bio-Techne Corporation
|
53
/ 100
| 111
| 6.0%
| 2.9%
| €20.20K
|
| Paratek Pharmaceuticals, Inc.
|
50
/ 100
| -1.9
| -40.0%
| -46.0%
| -€213.63K
|
| CorMedix Inc.
|
48
/ 100
| 17
| 42.1%
| 0.0%
| €681.82K
|
| Viridian Therapeutics, Inc.
|
50
/ 100
| -3.4
| -112,806.9%
| -59.1%
| -€2.05M
|
| Timber Pharmaceuticals, Inc.
|
50
/ 100
| -0.078
| -18,090.7%
| -452.4%
| -€1.43M
|
| Nxera Pharma Co., Ltd.
|
50
/ 100
| -25
| -10.5%
| -2.3%
| -€48.84K
|
| Enochian Biosciences, Inc.
|
50
/ 100
| -0.68
| -36,927.7%
| -56.9%
| -€2.60M
|
| Legend Biotech Corporation
|
50
/ 100
| -9.8
| -40.8%
| -19.3%
| -€106.87K
|
| Halozyme Therapeutics, Inc.
|
46
/ 100
| 12
| 47.3%
| 27.1%
| €1.36M
|
| ALK-Abelló A/S
|
51
/ 100
| 242
| 17.0%
| 12.1%
| €48.61K
|
| Equillium, Inc.
|
50
/ 100
| -0.55
| -122.0%
| -162.9%
| -€492.13K
|
| CytomX Therapeutics, Inc.
|
49
/ 100
| 7.4
| 34.0%
| 27.4%
| €343.93K
|
| Albireo Pharma, Inc.
|
50
/ 100
| -6.7
| -239.4%
| -42.8%
| -€901.37K
|
| Spero Therapeutics, Inc.
|
50
/ 100
| -3
| -134.5%
| -87.7%
| -€1.45M
|
| Relief Therapeutics Holding AG
|
50
/ 100
| -0.23
| -797.9%
| -216.6%
| -€3.98M
|
| Emmaus Life Sciences, Inc.
|
50
/ 100
| -0.28
| -24.2%
| -14.5%
| -€84.94K
|
| ABIVAX SA
|
50
/ 100
| -0.96
| -3,374.5%
| -311.6%
| -€5.40M
|
| Oragenics, Inc.
|
50
/ 100
| -0.28
| -328.1%
| -481.4%
| -€2.93M
|
| Champions Oncology, Inc.
|
50
/ 100
| 37
| 9.6%
| 9.6%
| €11.87K
|
| Ocular Therapeutix, Inc.
|
49
/ 100
| -6.8
| -382.9%
| -48.0%
| -€674.73K
|
| Stoke Therapeutics, Inc.
|
43
/ 100
| 12
| 26.3%
| 13.6%
| €349.74K
|
| Tissue Regenix Group plc
|
47
/ 100
| -11
| -5.3%
| -5.6%
| -€26.20K
|
| BioMarin Pharmaceutical Inc.
|
64
/ 100
| 16
| 21.5%
| 8.8%
| €184.41K
|
| Catalyst Pharmaceuticals, Inc.
|
52
/ 100
| 13
| 37.4%
| 21.5%
| €983.32K
|
| Clinuvel Pharmaceuticals Limited
|
54
/ 100
| 7.2
| 39.3%
| 26.4%
| €2.51M
|
| Clovis Oncology, Inc.
|
50
/ 100
| 0
| -242.9%
| -72.6%
| -€520.25K
|
| Genmab A/S
|
50
/ 100
| 11
| 32.7%
| 2.8%
| €378.10K
|
| OSE Immunotherapeutics SA
|
50
/ 100
| 7.8
| 20.0%
| 11.7%
| €225.66K
|
| Moderna, Inc.
|
64
/ 100
| -3.6
| -94.9%
| -24.2%
| -€426.92K
|
| Avid Bioservices, Inc.
|
50
/ 100
| -5.3
| -101.1%
| -47.0%
| -€349.57K
|
| XOMA Corporation
|
50
/ 100
| -28
| -31.0%
| -5.3%
| -€784.32K
|
| Novavax, Inc.
|
50
/ 100
| 2.4
| 40.7%
| 31.6%
| €378.83K
|
| Harpoon Therapeutics, Inc.
|
50
/ 100
| -28
| -82.7%
| -64.9%
| -€585.03K
|
| Northwest Biotherapeutics, Inc.
|
50
/ 100
| -4.2
| -7,548.7%
| -279.5%
| -€2.82M
|
| Revance Therapeutics, Inc.
|
50
/ 100
| -2.1
| -73.5%
| -39.3%
| -€259.23K
|
| AVEO Pharmaceuticals, Inc.
|
50
/ 100
| 0
| -44.6%
| -40.0%
| -€303.19K
|
| Alterity Therapeutics Limited
|
50
/ 100
| -2.8
| -448.2%
| -304.1%
| -€1.80M
|
| Geron Corporation
|
50
/ 100
| -11
| -53.5%
| -15.9%
| -€327.81K
|
| Veracyte, Inc.
|
55
/ 100
| 81
| 5.5%
| 2.0%
| €27.26K
|
| Nanobiotix S.A.
|
50
/ 100
| -1.7
| -438.4%
| -159.9%
| -€998.44K
|
| Poxel S.A.
|
50
/ 100
| -0.51
| -1,616.1%
| -1,079.9%
| -€10.06M
|
| Navidea Biopharmaceuticals, Inc.
|
50
/ 100
| -0.0085
| -193,849.2%
| -20.7%
| -€91.69K
|
| Akebia Therapeutics, Inc.
|
51
/ 100
| -26
| -17.9%
| -10.6%
| -€171.93K
|
| GeoVax Labs, Inc.
|
50
/ 100
| -0.42
| -468.8%
| -463.6%
| -€1.24M
|
| Adaptive Biotechnologies Corporation
|
52
/ 100
| -15
| -59.1%
| -24.4%
| -€167.05K
|
| Oxford BioDynamics Plc
|
50
/ 100
| -0.32
| -1,954.0%
| -184.9%
| -€503.82K
|
| Barinthus Biotherapeutics plc
|
50
/ 100
| -0.69
| -184.9%
| -41.6%
| -€437.55K
|
| Eiger BioPharmaceuticals, Inc.
|
50
/ 100
| -0.034
| -475.3%
| -193.0%
| -€1.14M
|
| Novo Nordisk A/S
|
65
/ 100
| 17
| 35.6%
| 23.0%
| €192.23K
|
| MedinCell S.A.
|
50
/ 100
| -9.6
| -240.6%
| -98.3%
| -€441.75K
|
| Oncopeptides AB (publ)
|
47
/ 100
| -1.1
| -696.7%
| -160.1%
| -€310.72K
|
| Genus plc
|
53
/ 100
| 49
| 2.0%
| 3.0%
| €8.92K
|
| Outlook Therapeutics, Inc.
|
48
/ 100
| -1.6
| -2,885.8%
| -194.0%
| -€1.61M
|
| Citius Pharmaceuticals, Inc.
|
50
/ 100
| -0.4
| -27,348.4%
| -35.1%
| -€1.58M
|
| Applied Therapeutics, Inc.
|
50
/ 100
| -0.68
| -55,982.6%
| -181.4%
| -€1.65M
|
| BioRestorative Therapies, Inc.
|
50
/ 100
| -1.1
| -1,771.9%
| -125.9%
| -€831.52K
|
| Crinetics Pharmaceuticals, Inc.
|
47
/ 100
| -7.6
| -26,568.5%
| -28.7%
| -€721.85K
|
| Marinus Pharmaceuticals, Inc.
|
50
/ 100
| -0.22
| -446.5%
| -220.8%
| -€726.25K
|
| Ardelyx, Inc.
|
49
/ 100
| -16
| -14.6%
| -12.1%
| -€121.76K
|
| FibroGen, Inc.
|
50
/ 100
| -19
| 2.8%
| -1.2%
| -€7.83K
|
| Pulmatrix, Inc.
|
50
/ 100
| -3.2
| -2,149.1%
| -128.9%
| -€3.38M
|
| Liquidia Corporation
|
44
/ 100
| -11
| -517.0%
| -38.8%
| -€501.19K
|
| BioCryst Pharmaceuticals, Inc.
|
51
/ 100
| -55
| -6.4%
| -7.8%
| -€52.52K
|
| TFF Pharmaceuticals, Inc.
|
50
/ 100
| -0.016
| -1,040.1%
| -261.7%
| -€831.48K
|
| Heidelberg Pharma AG
|
51
/ 100
| -11
| -377.9%
| -34.5%
| -€205.15K
|
| Bolt Biotherapeutics, Inc.
|
50
/ 100
| -0.29
| -1,217.0%
| -67.2%
| -€831.84K
|
| Novan, Inc.
|
50
/ 100
| 2.6
| 4.0%
| 1.3%
| €9.47K
|
| Pharma Mar, S.A.
|
50
/ 100
| 33
| 22.2%
| 12.1%
| €84.02K
|
| IGM Biosciences, Inc.
|
48
/ 100
| -1.2
| -36.8%
| -49.9%
| -€305.60K
|
| Mereo BioPharma Group plc
|
50
/ 100
| -8.5
| -9,910.0%
| -79.1%
| -€1.17M
|
| BioInvent International AB (publ)
|
50
/ 100
| -7.9
| -114.8%
| -31.8%
| -€221.57K
|
| Soligenix, Inc.
|
50
/ 100
| -0.6
| -116,624.3%
| -128.6%
| -€451.33K
|
| Evolva Holding SA
|
50
/ 100
| -0.084
| -2,414.2%
| -1,330.7%
| -€2.19M
|
| Sensorion SA
|
50
/ 100
| -2.4
| -393.1%
| -53.8%
| -€762.47K
|
| Ocugen, Inc.
|
50
/ 100
| -5
| -1,197.7%
| -106.2%
| -€511.22K
|
| Dianthus Therapeutics, Inc.
|
50
/ 100
| -4.9
| -2,364.1%
| -35.2%
| -€1.25M
|
| Vertex Pharmaceuticals Incorporated
|
73
/ 100
| 31
| 31.9%
| 15.1%
| €508.64K
|
| Zai Lab Limited
|
51
/ 100
| -18
| -49.7%
| -18.3%
| -€96.99K
|
| Zealand Pharma A/S
|
50
/ 100
| 4
| 73.3%
| 38.9%
| €2.32M
|
| ImmuPharma plc
|
50
/ 100
| -5.1
| 3,519.2%
| -60.6%
| -€565.00K
|
| Infinity Pharmaceuticals, Inc.
|
50
/ 100
| -0.018
| -1,553.4%
| -188.0%
| -€1.13M
|
| Camurus AB (publ)
|
54
/ 100
| 50
| 31.7%
| 16.2%
| €270.31K
|
| UCB SA
|
52
/ 100
| 21
| 12.3%
| 8.1%
| €155.55K
|
| Gritstone bio, Inc.
|
50
/ 100
| -0.029
| -7,825.5%
| -93.3%
| -€491.21K
|
| Takara Bio Inc.
|
52
/ 100
| 167
| 1.3%
| 0.4%
| €1.82K
|
| Gubra A/S
|
50
/ 100
| -106
| -17.2%
| -13.2%
| -€41.75K
|
| Transgene SA
|
51
/ 100
| -1.5
| -1,826.6%
| -145.6%
| -€414.53K
|
| Matinas BioPharma Holdings, Inc.
|
50
/ 100
| -0.24
| -2,038.4%
| -171.6%
| -€5.58M
|
| GB Sciences, Inc.
|
50
/ 100
| -0.12
| -1,073.0%
| -1,104.5%
| -€444.97K
|
| Adverum Biotechnologies, Inc.
|
51
/ 100
| -0.31
| 6,008.8%
| -162.4%
| -€859.71K
|
| Agenus Inc.
|
50
/ 100
| -0.79
| -162.7%
| -89.4%
| -€446.77K
|
| Adagene Inc.
|
51
/ 100
| -1.3
| -53,719.2%
| -83.3%
| -€342.67K
|
| Krystal Biotech, Inc.
|
49
/ 100
| 27
| 40.8%
| 12.9%
| €455.09K
|
| Lipocine Inc.
|
50
/ 100
| -3.9
| -107.1%
| -24.3%
| -€240.28K
|
| Vanda Pharmaceuticals Inc.
|
51
/ 100
| -4.2
| -32.9%
| -10.7%
| -€155.15K
|
| EyePoint Pharmaceuticals, Inc.
|
50
/ 100
| -4.5
| -261.9%
| -40.5%
| -€758.77K
|
| Cardiff Oncology, Inc.
|
51
/ 100
| -4.1
| -9,345.2%
| -67.4%
| -€1.36M
|
| BRAIN Biotech AG
|
50
/ 100
| -2.7
| -22.4%
| -18.9%
| -€51.22K
|
| Alector, Inc.
|
50
/ 100
| -1.3
| -142.1%
| -32.3%
| -€561.92K
|
| Valneva SE
|
50
/ 100
| -6.1
| -34.1%
| -14.2%
| -€94.03K
|
| Traws Pharma, Inc.
|
50
/ 100
| -0.5
| -613.9%
| -114.1%
| -€2.53M
|
| Quantum Genomics SA
|
50
/ 100
| -0.16
| -3,440.5%
| -833.1%
| -€10.40M
|
| Gossamer Bio, Inc.
|
50
/ 100
| -2
| -344.8%
| -57.6%
| -€821.81K
|
| Oxford Biomedica plc
|
50
/ 100
| -1.4
| -91.9%
| -86.6%
| -€270.91K
|
| Blueprint Medicines Corporation
|
58
/ 100
| -53
| -27.7%
| -13.0%
| -€194.77K
|
| Adocia SA
|
50
/ 100
| -2.3
| -265.8%
| -112.8%
| -€401.09K
|
| Lineage Cell Therapeutics, Inc.
|
50
/ 100
| -5.2
| -374.8%
| -45.1%
| -€498.49K
|
| Aligos Therapeutics, Inc.
|
50
/ 100
| -0.59
| -2,337.2%
| -55.1%
| -€903.93K
|
| Immutep Limited
|
50
/ 100
| -4.3
| -957.6%
| -46.3%
| -€1.15M
|
| Kineta, Inc.
|
50
/ 100
| -0.92
| -177.5%
| -914.3%
| -€596.91K
|
| Kura Oncology, Inc.
|
50
/ 100
| -2.5
| -236.8%
| -28.9%
| -€875.93K
|
| Clearside Biomedical, Inc.
|
50
/ 100
| -2.2
| -665.2%
| -180.7%
| -€738.66K
|
| Generex Biotechnology Corporation
|
50
/ 100
| 0
| -567.4%
| -8.6%
| -€223.53K
|
| KalVista Pharmaceuticals, Inc.
|
48
/ 100
| -2.8
| -14,242.4%
| -94.2%
| -€1.15M
|
| Syndax Pharmaceuticals, Inc.
|
48
/ 100
| -2.3
| -428.5%
| -56.2%
| -€1.06M
|
| Oxford Nanopore Technologies plc
|
50
/ 100
| -4.3
| -85.2%
| -40.5%
| -€249.66K
|
| WuXi Biologics (Cayman) Inc.
|
51
/ 100
| 14
| 18.9%
| 11.9%
| €63.92K
|
| Reata Pharmaceuticals, Inc.
|
50
/ 100
| -82
| -328.2%
| -15.9%
| -€212.72K
|
| Surface Oncology, Inc.
|
50
/ 100
| -0.69
| -313.4%
| -142.4%
| -€2.29M
|
| vTv Therapeutics Inc.
|
51
/ 100
| -1.9
| -115,029.4%
| -73.9%
| -€725.19K
|
| Catalyst Biosciences, Inc.
|
50
/ 100
| 15
| 13.7%
| 13.4%
| €2.57M
|
| Pharming Group N.V.
|
50
/ 100
| -91
| -2.4%
| -1.8%
| -€17.31K
|
| Provectus Biopharmaceuticals, Inc.
|
50
/ 100
| -4.9
| -1,827.1%
| -886.4%
| -€910.24K
|
| Ultragenyx Pharmaceutical Inc.
|
51
/ 100
| -6.5
| -87.3%
| -40.8%
| -€351.29K
|
| Verastem, Inc.
|
50
/ 100
| -1.4
| -7,793.9%
| -84.9%
| -€1.82M
|
| Can-Fite BioPharma Ltd.
|
50
/ 100
| -1.8
| -1,005.7%
| -74.8%
| -€1.27M
|
| Cyclacel Pharmaceuticals, Inc.
|
50
/ 100
| -1.7
| 25,632.0%
| -145,603.3%
| -€455.48K
|
| Intellia Therapeutics, Inc.
|
56
/ 100
| -2.1
| -908.5%
| -53.4%
| -€1.02M
|
| PHAXIAM Therapeutics S.A.
|
50
/ 100
| -0.91
| -1,023.9%
| -56.1%
| -€447.39K
|
| Rhythm Pharmaceuticals, Inc.
|
46
/ 100
| -22
| -118.0%
| -49.5%
| -€555.75K
|
| PureTech Health plc
|
50
/ 100
| -35
| -155.2%
| -2.0%
| -€126.49K
|
| Fate Therapeutics, Inc.
|
50
/ 100
| -0.7
| -2,025.1%
| -46.2%
| -€808.29K
|
| Sorrento Therapeutics, Inc.
|
50
/ 100
| -0.03
| -854.5%
| -120.3%
| -€493.62K
|
| Enanta Pharmaceuticals, Inc.
|
50
/ 100
| -1.7
| -142.0%
| -30.6%
| -€599.10K
|
| ImmunityBio, Inc.
|
50
/ 100
| -6.5
| -648.6%
| -91.3%
| -€466.63K
|
| Sage Therapeutics, Inc.
|
50
/ 100
| -1.9
| -427.8%
| -71.2%
| -€727.78K
|
| TG Therapeutics, Inc.
|
55
/ 100
| 149
| 10.1%
| 6.0%
| €94.87K
|
| Innate Pharma S.A.
|
50
/ 100
| -2.5
| -77.6%
| -51.4%
| -€315.14K
|
| GenSight Biologics S.A.
|
50
/ 100
| -0.66
| -909.4%
| -373.9%
| -€2.51M
|
| REGENXBIO Inc.
|
50
/ 100
| -2.4
| -112.7%
| -30.2%
| -€424.23K
|
| Ampio Pharmaceuticals, Inc.
|
50
/ 100
| -0.00036
| -3,523.3%
| -150.5%
| -€1.23M
|
| NexImmune, Inc.
|
50
/ 100
| -0.0000067
| -972.2%
| -351.7%
| -€2.93M
|
| BioLineRx Ltd.
|
50
/ 100
| -45
| -45.3%
| -18.1%
| -€238.28K
|
| NRx Pharmaceuticals, Inc.
|
50
/ 100
| -0.042
| -844,850.0%
| -698.5%
| -€14.41M
|
| Hansa Biopharma AB (publ)
|
50
/ 100
| -3.1
| -303.4%
| -71.2%
| -€386.88K
|
| Bellerophon Therapeutics, Inc.
|
50
/ 100
| -0.013
| -206.9%
| -234.4%
| -€553.00K
|
| Revolution Medicines, Inc.
|
47
/ 100
| -8.5
| -310.4%
| -33.4%
| -€1.12M
|
| La Jolla Pharmaceutical Company
|
50
/ 100
| 0
| 3.3%
| 1.5%
| €21.27K
|
| Ionis Pharmaceuticals, Inc.
|
47
/ 100
| -24
| -28.4%
| -9.0%
| -€214.01K
|
| CymaBay Therapeutics, Inc.
|
50
/ 100
| -33
| -359.4%
| -25.7%
| -€943.11K
|
| Molecular Partners AG
|
49
/ 100
| -1.7
| -9,516.2%
| -52.2%
| -€439.00K
|
| Celyad Oncology SA
|
50
/ 100
| -1.2
| -4,955.2%
| -143.7%
| -€839.47K
|
| Avacta Group Plc
|
49
/ 100
| -1.8
| -175.9%
| -76.1%
| -€506.49K
|
| Xenetic Biosciences, Inc.
|
50
/ 100
| -1.8
| -126.0%
| -57.6%
| -€1.31M
|
| Addex Therapeutics Ltd
|
50
/ 100
| 1.3
| 5,081.4%
| 91.4%
| €403.47K
|
| Ocuphire Pharma, Inc.
|
49
/ 100
| -0.52
| 9,429.1%
| -157.8%
| -€3.72M
|
| Atreca, Inc.
|
50
/ 100
| -0.038
| -36,151.0%
| -360.9%
| -€901.07K
|
| Concert Pharmaceuticals, Inc.
|
50
/ 100
| 0
| -117,455.6%
| -38.8%
| -€885.66K
|
| Genfit S.A.
|
50
/ 100
| -8.5
| -20.4%
| -12.8%
| -€114.48K
|
| OncoCyte Corporation
|
50
/ 100
| -1.4
| -1,489.7%
| -125.5%
| -€1.18M
|
| AnGes, Inc.
|
50
/ 100
| -0.81
| -3,940.3%
| -485.1%
| -€2.89M
|
| ChromaDex Corporation
|
53
/ 100
| 35
| 20.8%
| 19.4%
| €145.40K
|
| Karyopharm Therapeutics Inc.
|
50
/ 100
| -0.31
| -90.0%
| -117.8%
| -€377.76K
|
| Laboratorios Farmaceuticos Rovi, S.A.
|
51
/ 100
| 14
| 20.5%
| 23.2%
| €91.68K
|
| Adaptimmune Therapeutics plc
|
48
/ 100
| -0.37
| -260.8%
| -129.9%
| -€286.15K
|
| Kuros Biosciences AG
|
47
/ 100
| -60
| -16.5%
| -21.3%
| -€158.07K
|
| Heron Therapeutics, Inc.
|
52
/ 100
| -351
| -0.6%
| -0.4%
| -€6.51K
|
| KemPharm, Inc.
|
50
/ 100
| -4.2
| -80.9%
| -18.7%
| -€1.71M
|
| Armata Pharmaceuticals, Inc.
|
50
/ 100
| -2.8
| -755.2%
| -31.8%
| -€365.45K
|
| NovaBay Pharmaceuticals, Inc.
|
47
/ 100
| 1.1
| 70.0%
| 48.1%
| €218.09K
|
| Sangamo Therapeutics, Inc.
|
50
/ 100
| -2.1
| -77.5%
| -64.9%
| -€295.07K
|
| Voyager Therapeutics, Inc.
|
51
/ 100
| -1.5
| -253.5%
| -33.5%
| -€535.25K
|
| Cytokinetics, Incorporated
|
46
/ 100
| -6.5
| -707.2%
| -49.5%
| -€1.04M
|
| Immunocore Holdings plc
|
46
/ 100
| -77
| -5.7%
| -1.9%
| -€35.14K
|
| Omeros Corporation
|
50
/ 100
| -1.5
| -29,726.7%
| -61.1%
| -€517.15K
|
| Deinove SA
|
50
/ 100
| -0.12
| -9,039.6%
| -65.8%
| -€207.50K
|
| Precision BioSciences, Inc.
|
50
/ 100
| -0.61
| -6,205.8%
| -71.8%
| -€618.03K
|
| Idorsia Ltd
|
50
/ 100
| -3.1
| -62.4%
| -26.8%
| -€224.27K
|
| Silence Therapeutics plc
|
50
/ 100
| -20
| -314.6%
| -10.7%
| -€98.22K
|
| Larimar Therapeutics, Inc.
|
50
/ 100
| -1.9
| -41,405.0%
| -66.5%
| -€1.31M
|
| IXICO plc
|
50
/ 100
| -3
| -25.6%
| -28.4%
| -€45.03K
|
| ImmunoGen, Inc.
|
50
/ 100
| -119
| -25.4%
| -8.9%
| -€225.01K
|
| argenx SE
|
52
/ 100
| 38
| 31.4%
| 12.5%
| €477.36K
|
| PhaseBio Pharmaceuticals, Inc.
|
50
/ 100
| 0
| 3,402.9%
| 125.6%
| €395.71K
|
| Acer Therapeutics Inc.
|
50
/ 100
| 0
| -13,041.5%
| -346.3%
| -€1.38M
|
| Polyphor AG
|
50
/ 100
| 0
| -1,760.7%
| -50.4%
| -€1.19M
|
| Oramed Pharmaceuticals Inc.
|
50
/ 100
| -3.6
| -1,208.1%
| -14.9%
| -€1.59M
|
| Cara Therapeutics, Inc.
|
51
/ 100
| -0.39
| -317.5%
| -47.8%
| -€1.78M
|
| Starpharma Holdings Limited
|
50
/ 100
| -1.5
| -200.6%
| -64.7%
| -€333.34K
|
| Curis, Inc.
|
50
/ 100
| -0.58
| -341.2%
| -133.1%
| -€976.35K
|
| ReNeuron Group plc
|
50
/ 100
| -0.15
| -1,231.0%
| -197.8%
| -€560.66K
|
| Amicus Therapeutics, Inc.
|
51
/ 100
| -48
| -6.7%
| -4.7%
| -€65.12K
|
| Alpine Immune Sciences, Inc.
|
50
/ 100
| -121
| -65.2%
| -9.9%
| -€221.26K
|
| BB Biotech AG
|
52
/ 100
| -3.9
| 263.0%
| -21.8%
| -€45.55M
|
| Verrica Pharmaceuticals Inc.
|
50
/ 100
| -0.99
| -330.5%
| -124.3%
| -€583.85K
|
| Ascendis Pharma A/S
|
49
/ 100
| -33
| -55.3%
| -24.9%
| -€266.62K
|
| Chimerix, Inc.
|
46
/ 100
| -9.1
| -41,692.0%
| -60.5%
| -€954.30K
|
| Coherus BioSciences, Inc.
|
50
/ 100
| 0.48
| 125.9%
| 40.9%
| €672.45K
|
| scPharmaceuticals Inc.
|
50
/ 100
| -2.2
| -183.5%
| -114.3%
| -€482.90K
|
| NGM Biopharmaceuticals, Inc.
|
50
/ 100
| -0.92
| -3,165.7%
| -82.8%
| -€864.25K
|
| Carisma Therapeutics, Inc.
|
50
/ 100
| -0.34
| -458.6%
| -985.2%
| -€915.57K
|
| Verona Pharma plc
|
49
/ 100
| -98
| -36.6%
| -14.2%
| -€331.33K
|
| Amarin Corporation plc
|
50
/ 100
| -63
| -53.6%
| -15.5%
| -€321.29K
|
| Centessa Pharmaceuticals plc
|
46
/ 100
| -7.6
| -1,535.8%
| -46.8%
| -€2.55M
|
| Genprex, Inc.
|
50
/ 100
| -0.37
| -174,323.8%
| -451.6%
| -€982.94K
|
| Inventiva S.A.
|
50
/ 100
| -1.2
| -777.7%
| -247.7%
| -€2.58M
|
| Alnylam Pharmaceuticals, Inc.
|
64
/ 100
| -132
| -13.0%
| -7.0%
| -€122.05K
|
| Cartesian Therapeutics, Inc.
|
50
/ 100
| -7.6
| -3,534.1%
| -9.3%
| -€468.61K
|
| Santhera Pharmaceuticals Holding AG
|
50
/ 100
| 12
| 9.0%
| 8.4%
| €175.75K
|
| Marker Therapeutics, Inc.
|
50
/ 100
| -1.1
| -271.1%
| -98.9%
| -€2.49M
|
| Savara Inc.
|
50
/ 100
| -3.5
| -40,563.2%
| -67.4%
| -€1.60M
|
| Codexis, Inc.
|
51
/ 100
| -3
| -113.7%
| -47.0%
| -€294.79K
|
| BioNTech SE
|
68
/ 100
| -63
| -12.1%
| -1.6%
| -€51.31K
|
| Provention Bio, Inc.
|
50
/ 100
| -21
| -876.1%
| -47.7%
| -€553.80K
|
| ObsEva SA
|
50
/ 100
| 0.022
| 33.9%
| 87.8%
| €450.47K
|
| Nektar Therapeutics
|
50
/ 100
| -2.6
| -163.2%
| -58.9%
| -€1.71M
|
| IDEAYA Biosciences, Inc.
|
49
/ 100
| -5.7
| -4,729.0%
| -31.8%
| -€2.16M
|
| United Therapeutics Corporation
|
62
/ 100
| 10
| 40.4%
| 15.7%
| €811.84K
|
| Spectrum Pharmaceuticals, Inc.
|
50
/ 100
| -3.2
| -252.5%
| -60.4%
| -€645.23K
|
| Ovid Therapeutics Inc.
|
50
/ 100
| -0.56
| -574.0%
| -49.3%
| -€1.42M
|
| Fortress Biotech, Inc.
|
50
/ 100
| -3.7
| -24.8%
| -9.2%
| -€124.40K
|
| IntelGenx Technologies Corp.
|
50
/ 100
| -2.7
| -1,049.5%
| -168.4%
| -€196.00K
|
| BioXcel Therapeutics, Inc.
|
48
/ 100
| -0.21
| -5,869.8%
| -197.6%
| -€1.17M
|
| Roquefort Therapeutics plc
|
50
/ 100
| -0.62
| -1,567.4%
| -52.3%
| -€520.81K
|
| Corcept Therapeutics Incorporated
|
61
/ 100
| 59
| 18.5%
| 16.5%
| €226.06K
|
| Sarepta Therapeutics, Inc.
|
51
/ 100
| -29
| -2.3%
| -1.6%
| -€36.03K
|
| PTC Therapeutics, Inc.
|
46
/ 100
| 6.3
| 35.6%
| 23.9%
| €571.52K
|
| Basilea Pharmaceutica AG
|
48
/ 100
| 6.6
| 24.0%
| 34.2%
| €574.61K
|
| Agios Pharmaceuticals, Inc.
|
46
/ 100
| 3
| 1,590.4%
| 44.2%
| €1.14M
|
| Plus Therapeutics, Inc.
|
50
/ 100
| -0.84
| -776.9%
| -183.8%
| -€772.81K
|
| Cellectis S.A.
|
50
/ 100
| -1.8
| -104.8%
| -16.7%
| -€232.97K
|
| Precigen, Inc.
|
47
/ 100
| -3.4
| -2,868.7%
| -122.2%
| -€742.60K
|
| BeiGene, Ltd.
|
29
/ 100
| -187
| -3.9%
| -2.8%
| -€14.29K
|
| E-therapeutics Plc
|
50
/ 100
| -2.9
| -2,451.5%
| -77.9%
| -€656.07K
|
| Immuron Limited
|
50
/ 100
| -1.4
| -111.0%
| -92.3%
| -€898.97K
|
